Martin Gill brings more than 12 years of experience in the pharmaceutical industry to this team. He received his PhD in neuroscience and cell biology from The University of Texas-Medical Branch and completed postdoctoral training at Northwestern University. Dr. Gill has led and contributed to teams developing small molecule, antisense oligonucleotide and immunotherapy approaches to treating neurogenerative disease.
Associated Grants
-
Testing Small Molecules that Activate Removal of Cellular Debris for the Treatment of Parkinson’s Disease
2022
-
Developing TLR2-Blocking Drugs to Reduce Alpha-synuclein-Induced Inflammation in Parkinson's Disease
2018
-
Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release
2017